Skip to main content
CMII
NASDAQ Life Sciences

Elroy Air Secures $46M U.S. Army Contract for Autonomous VTOL Cargo Drone

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.4
Mkt Cap
$314.57M
52W Low
$9.756
52W High
$10.22
52W Position info
6.6% above low
Off High info
at 52W high
Rel. Volume info
3.7× avg
Market data snapshot near publication time

CMII is trading near its 52-week low of $9.756 (6.6% above the low) on elevated volume (3.7× avg).

Summary

Elroy Air, the target of Columbus Circle Capital Corp II's pending SPAC merger, won a $46.1 million U.S. Army contract to develop an autonomous VTOL cargo drone, with $5.1 million obligated immediately and work expected through 2029.


Key Events · M&A and Partnerships · CMII

  • U.S. Army Contract Award

    A $46,058,871 firm-fixed-price contract has been awarded to Elroy Air for development of an autonomous hybrid-electric VTOL uncrewed aircraft system for modular multi-mission payload delivery.

  • Initial Funding Obligated

    Fiscal Year 2026 research, development, test and evaluation funds of $5,135,354 were obligated at the time of award.

  • Contract Timeline

    Work will be performed in California with an estimated completion date in 2029.

  • Merger Context

    The contract strengthens Elroy Air's position ahead of the expected Q4 2026 close of its $1 billion SPAC merger with Columbus Circle Capital Corp II.


Analysis · CMII · Life Sciences

A $46.1 million firm-fixed-price contract from the U.S. Army has been awarded to Elroy Air, the target of Columbus Circle Capital Corp II's pending SPAC merger, to develop an autonomous hybrid-electric VTOL aircraft for modular multi-mission payload delivery. This award validates Elroy Air's technology and provides a concrete revenue stream ahead of the merger's expected Q4 2026 close. While the contract is subject to government termination for convenience and future funding depends on option exercise and annual budget approvals, the initial $5.1 million obligation and multi-year development timeline strengthen the investment thesis for the combined company.

At the time of this filing, CMII was trading at $10.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $314.6M. The 52-week trading range was $9.76 to $10.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CMII - Latest Insights

CMII
Aug 21, 2026, 4:31 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $10.20
Real-time Price: $10.09 info
Change: -$0.110 (-1%) info
Market Cap: $314.57M info
CMII
Aug 19, 2026, 5:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.04
Real-time Price: $10.09 info
Change: +$0.050 (+0.50%) info
Market Cap: $314.57M info
CMII
Aug 18, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $9.98
Real-time Price: $10.09 info
Change: +$0.1081 (+1%) info
Market Cap: $314.57M info
CMII
Aug 12, 2026, 4:05 PM EDT
Filing Type: 425
Importance Score:
7
Price at Filing: $10.02
Real-time Price: $10.09 info
Change: +$0.070 (+0.70%) info
Market Cap: $314.57M info
CMII
Jul 29, 2026, 8:53 PM EDT
Filing Type: 425
Importance Score:
7
Price at Filing: $10.00
Real-time Price: $10.09 info
Change: +$0.090 (+0.90%) info
Market Cap: $314.57M info